SCHEDULE: RA Capital Management Boosts Ovid Therapeutics Stake to 9.9%

RA Capital Management and its affiliates now beneficially own 9.9% of Ovid Therapeutics' common stock, primarily through warrants and direct holdings, as of June 30, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have collectively increased their beneficial ownership in Ovid Therapeutics Inc. to 9.9% as of June 30, 2026.
• The total beneficial ownership amounts to 19,549,271 shares of common stock.
• This ownership includes direct holdings of 10,500,968 shares, pre-funded warrants exercisable for up to 5,013,426 shares, and Series B warrants exercisable for up to 5,357,000 shares.
• Beneficial ownership is capped at 9.99% due to 'Beneficial Ownership Blocker' provisions in the warrants, limiting exercise to prevent exceeding this threshold.
• RA Capital Management acts as the investment adviser for the Fund and has been delegated sole voting and dispositive power over the Fund's securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant beneficial ownership by RA Capital Management and its affiliates, which often suggests confidence in the company's future prospects.

Positives

• Significant increase in beneficial ownership by a major investment firm (RA Capital Management) to 9.9% suggests strong conviction in Ovid Therapeutics' potential.
• The reporting persons hold a substantial number of shares (19,549,271) and warrants, indicating a considerable investment.
• Delegation of voting and dispositive power to RA Capital Management centralizes decision-making and strategic alignment.

Negatives

• The 'Beneficial Ownership Blocker' provisions in the warrants limit the ability to exercise them fully, capping ownership at 19,549,271 shares or 9.99% of the outstanding stock.
• The Fund disclaims beneficial ownership of the securities it holds due to the divestment of voting and investment power, which could be a complex reporting nuance.

Risks

• The 'Beneficial Ownership Blocker' feature in the warrants poses a risk by limiting the reporting persons' ability to increase their stake beyond 9.99%, potentially hindering further investment or influence.
• Reliance on warrant exercise for a significant portion of ownership means the ultimate share count is contingent on warrant terms and market conditions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Ovid Therapeutics. The outlook is inferred from RA Capital Management's increased stake, suggesting a positive view on the company's future potential.

Management Comments

• RA Capital Management serves as investment adviser for the Fund and may be deemed a beneficial owner of securities held by the Fund.
• Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners of securities beneficially owned by RA Capital.
• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• The Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, leading the Fund to disclaim beneficial ownership.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported other than for the purpose of determining obligations under Section 13(d) of the Act.

Industry Context

StockSavvy.ai notes that significant stake increases by institutional investors like RA Capital Management in biotechnology or pharmaceutical companies often signal a belief in the company's pipeline or upcoming milestones. This filing suggests RA Capital sees value in Ovid Therapeutics' current position and future prospects within the competitive biotech landscape.

Stakeholder Impact

• Shareholders may view the increased stake by RA Capital as a positive signal, potentially boosting investor confidence.
• The capped ownership due to warrant blockers might limit the potential for a hostile takeover or significant activist influence from RA Capital.
• Creditors and other stakeholders may see the increased institutional interest as a sign of stability and potential growth for Ovid Therapeutics.

Next Steps

• Continued monitoring of RA Capital Management's holdings and any further filings.
• Observation of Ovid Therapeutics' strategic developments and financial performance.

Key Dates

Recommendation

The filing indicates a significant increase in beneficial ownership by RA Capital Management, suggesting confidence. However, the ownership is capped by warrant provisions, and the filing itself is a disclosure of existing holdings rather than new strategic information. Therefore, a 'hold' recommendation is appropriate, pending further developments or catalysts from Ovid Therapeutics.

Keywords

Ovid Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Healthcare Fund, Investment Adviser, Securities Exchange Act